Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

MarketBeat

House cats with bird flu could pose risk

Pet owners probably shouldn't be afraid their cats will give them bird flu but taking precautions is good for pets

Salon

Musk Seemingly Calls for Term Limits as Federal Judge Orders HHS, CDC and FDA to Restore Deleted Webpages: 'Truly Absurd'

Elon Musk demands the removal of a federal judge after a ruling forcing HHS, CDC, and FDA to restore deleted webpages, calling it "truly absurd."

Latin Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Federal Judge Orders Restoration Of Health Webpages

Federal judge issues restraining order to restore health-related webpages removed due to executive order, impacting patient care and research.

Top News

Judge tells agencies to restore webpages and data removed after Trump's executive order

A federal judge has told government agencies to restore public access to health-related webpages and datasets they removed to comply with an executive order by President Donald Trump

The Independent UK

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

Investors Business Daily

2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

The recent advancements in their pipelines imply high growth potential in the coming years.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Ozempic, Wegovy maker claps back at Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Fortune

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

Investors Business Daily

Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

LiveScience

Tuna cans sold at Trader Joe’s, Walmart and Costco recalled due to contamination risk

The recall came after a manufacturing defect in the tuna cans’ ‘easy open’ lids was discovered

The Independent UK

McDonald's improving global sales help to offset US weakness in fourth quarter

Improving international sales helped McDonald’s overcome some weakness at home in the fourth quarter

The Independent UK

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Salon

Two million cases of donuts recalled over contamination risk

The recalled donuts were sold in the U.S. and Canada

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Hims stock surged Friday after facing backlash over its provocative Super Bowl ad.

International Business Times

FDA Warns Of Missed Alerts On Phone-Connected Diabetes Devices, Leading To 'Serious Harm'

The FDA issued an alert warning diabetes patients and caregivers about potential issues with smartphone alerts for continuous glucose monitors.

Salon

A gentler drug overdose reversal

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose

Top News

FDA Warns Of Health Risks From Diabetes App Notifications

FDA warns of health risks from missed alerts on diabetes management apps, emphasizing the need for proper device functioning to ensure patient safety.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.

The Independent UK

Patients using diabetes apps can miss critical alerts. Here's how to make sure you're getting them

U.S. officials are warning about a potentially life-threatening issue with smartphone apps that help manage diabetes

Salon

RFK Jr.'s plan for ultra-processed foods

Kennedy is Trump's top pick to lead the U.S. Department of Health and Human Services (HHS)

The Conversation

First new non-opioid painkiller approved in the US for decades – here’s how it works

A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency has approved in over two decades.

Fortune

Patients will pay more for prescription meds and face drug shortages amid Trump tariffs, pharma groups warn

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients.

MarketBeat

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

Investors Business Daily

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.